Marker Therapeutics Leads 3 Noteworthy US Penny Stocks

Simply Wall St.12-06

As the U.S. stock market takes a breather from its recent rally, investors are keenly watching for insights from upcoming economic reports and policy shifts. Despite the fluctuating conditions, penny ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489804832?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1W2Igu0.nhgjE8NeoLBgXg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/590bd73c4f469217441156accbe686a8","is_english":true,"pubTime":"2024-12-06 21:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489804832","market":"us","top_or_hot":-1,"title":"Marker Therapeutics Leads 3 Noteworthy US Penny Stocks","media":"Simply Wall St.","content":"<div>\n<p>As the U.S. stock market takes a breather from its recent rally, investors are keenly watching for insights from upcoming economic reports and policy shifts. Despite the fluctuating conditions, penny ...</p>\n\n<a href=\"https://finance.yahoo.com/news/marker-therapeutics-leads-3-noteworthy-130741430.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marker Therapeutics Leads 3 Noteworthy US Penny Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarker Therapeutics Leads 3 Noteworthy US Penny Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 21:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/marker-therapeutics-leads-3-noteworthy-130741430.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the U.S. stock market takes a breather from its recent rally, investors are keenly watching for insights from upcoming economic reports and policy shifts. Despite the fluctuating conditions, penny ...</p>\n\n<a href=\"https://finance.yahoo.com/news/marker-therapeutics-leads-3-noteworthy-130741430.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SB","symbol_name":"Safe Bulkers","start_time":0,"source_url":"https://finance.yahoo.com/news/marker-therapeutics-leads-3-noteworthy-130741430.html","article_id":"2489804832","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1W2Igu0.nhgjE8NeoLBgXg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/590bd73c4f469217441156accbe686a8"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489804832","pubTimestamp":1733490461,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"As the U.S. stock market takes a breather from its recent rally, investors are keenly watching for insights from upcoming economic reports and policy shifts. Despite the fluctuating conditions, penny stocks remain an intriguing segment for investors seeking growth opportunities in smaller or newer companies. Though often considered a niche area, these stocks can offer significant potential when backed by strong financial health and clear growth prospects.Overview: Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing novel T cell-based immunotherapies for hematological malignancies and solid tumors, with a market cap of $31.41 million.Click to explore a detailed breakdown of our findings in Marker Therapeutics' financial health report.Gain insights into Marker Therapeutics' outlook and expected performance with our report on the company's earnings estimates.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SB":"Safe Bulkers","BK4075":"烟草","BK4563":"昨日强势股","RLX":"雾芯科技","BK4551":"寇图资本持仓","BK4139":"生物科技","BABB":"BAB, Inc.","LENZ":"Therapeutics","BK4021":"海运","PVL":"Enduro Royalty Trust","BK4213":"石油与天然气的勘探与生产","DC":"Dakota Gold Corp","MRKR":"Marker Therapeutics, Inc.","BK4526":"热门中概股","BK4209":"餐馆"},"translate_title":"Marker Therapeutics领先3只值得关注的美国细价股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BABB":1,"LENZ":1,"PVL":1,"RLX":1,"SB":1,"DC":0.9,"MRKR":0.9},"content_text":"As the U.S. stock market takes a breather from its recent rally, investors are keenly watching for insights from upcoming economic reports and policy shifts. Despite the fluctuating conditions, penny stocks remain an intriguing segment for investors seeking growth opportunities in smaller or newer companies. Though often considered a niche area, these stocks can offer significant potential when backed by strong financial health and clear growth prospects.\nTop 10 Penny Stocks In The United States\n\n\n\nName\nShare Price\nMarket Cap\nFinancial Health Rating\n\n\nInter & Co (NasdaqGS:INTR)\n$4.53\n$1.91B\n★★★★☆☆\n\n\nBAB (OTCPK:BABB)\n$0.8675\n$6.17M\n★★★★★★\n\n\nQuantaSing Group (NasdaqGM:QSG)\n$3.08\n$157.43M\n★★★★★★\n\n\nImperial Petroleum (NasdaqCM:IMPP)\n$2.96\n$90.09M\n★★★★★★\n\n\nGolden Growers Cooperative (OTCPK:GGRO.U)\n$4.50\n$69.71M\n★★★★★★\n\n\nZTEST Electronics (OTCPK:ZTST.F)\n$0.235\n$8.83M\n★★★★★★\n\n\nPermianville Royalty Trust (NYSE:PVL)\n$1.5306\n$50.52M\n★★★★★★\n\n\nRLX Technology (NYSE:RLX)\n$1.81\n$2.33B\n★★★★★★\n\n\nZynerba Pharmaceuticals (NasdaqCM:ZYNE)\n$1.30\n$65.6M\n★★★★★☆\n\n\nCBAK Energy Technology (NasdaqCM:CBAT)\n$0.935\n$83.14M\n★★★★★☆\n\n\n\nClick here to see the full list of 711 stocks from our US Penny Stocks screener.\nHere we highlight a subset of our preferred stocks from the screener.\nMarker Therapeutics\nSimply Wall St Financial Health Rating: ★★★★★★\nOverview: Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing novel T cell-based immunotherapies for hematological malignancies and solid tumors, with a market cap of $31.41 million.\nOperations: The company generates revenue from its Biotechnology (Startups) segment, amounting to $7.48 million.\nMarket Cap: $31.41M\nMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, has shown significant revenue growth from US$0.26 million to US$1.93 million year-over-year for Q3 2024, though it remains unprofitable with a net loss of US$2.31 million. The company recently filed a shelf registration for up to $300 million and an $11.43 million follow-on equity offering, indicating efforts to bolster its financial position amid ongoing development activities. Despite having no debt and sufficient short-term assets exceeding liabilities, the stock remains highly volatile with limited profitability prospects in the near term but shows potential revenue growth opportunities ahead.\n\nClick to explore a detailed breakdown of our findings in Marker Therapeutics' financial health report.\nGain insights into Marker Therapeutics' outlook and expected performance with our report on the company's earnings estimates.\n\n\n\n\n  NasdaqCM:MRKR Debt to Equity History and Analysis as at Dec 2024\n \n\nDakota Gold\nSimply Wall St Financial Health Rating: ★★★★★☆\nOverview: Dakota Gold Corp. is involved in the acquisition, exploration, and development of mineral properties in the United States, with a market cap of approximately $200.19 million.\nOperations: Dakota Gold Corp. currently does not report any specific revenue segments.\nMarket Cap: $200.19M\nDakota Gold Corp., with a market cap of US$200.19 million, remains pre-revenue and unprofitable, reporting a net loss of US$10.09 million for Q3 2024. The company is debt-free but has less than a year of cash runway based on current free cash flow trends. Recent exploration at the Maitland Gold Project has extended the known mineralization significantly, showing high-grade gold intercepts that could enhance future value if developed successfully. Leadership changes include Robert Quartermain's appointment as CEO, bringing experience from his previous roles in successful mining ventures to guide Dakota Gold's strategic direction and project execution efforts.\n\nDive into the specifics of Dakota Gold here with our thorough balance sheet health report.\nGain insights into Dakota Gold's historical outcomes by reviewing our past performance report.\n\n\n\n\n  NYSEAM:DC Financial Position Analysis as at Dec 2024\n \n\nSafe Bulkers\nSimply Wall St Financial Health Rating: ★★★★☆☆\nOverview: Safe Bulkers, Inc., along with its subsidiaries, offers marine drybulk transportation services and has a market cap of approximately $400.42 million.\nOperations: The company's revenue is derived entirely from its transportation - shipping segment, totaling $318.43 million.\nMarket Cap: $400.42M\nSafe Bulkers, Inc., with a market cap of approximately US$400.42 million, has demonstrated robust financial performance with Q3 2024 revenue reaching US$75.92 million, up from US$64.65 million the previous year. The company reported net income of US$25.12 million for the quarter and announced a share repurchase program to buy back up to 5% of its outstanding shares, funded by existing cash resources. Despite high debt levels and a low return on equity at 12.8%, Safe Bulkers benefits from stable weekly volatility and improved profit margins, currently at 30.7%.\n\nClick here and access our complete financial health analysis report to understand the dynamics of Safe Bulkers.\nExplore Safe Bulkers' analyst forecasts in our growth report.\n\n\n\n\n  NYSE:SB Debt to Equity History and Analysis as at Dec 2024\n \n\nWhere To Now?\n\nGain an insight into the universe of 711  US Penny Stocks by clicking here.\nHold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.\nSimply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.\n\nInterested In Other Possibilities?\n\nExplore high-performing small cap companies that haven't yet garnered significant analyst attention.\nJump on the AI train with fast growing tech companies forging a new era of innovation.\nFind companies with promising cash flow potential yet trading below their fair value.\n\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\nCompanies discussed in this article include NasdaqCM:MRKR NYSEAM:DC and NYSE:SB.\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489804832"}